Floatz logo

Zenocutuzumab

Prostate Cancer

monoclonal_antibodyDormant
D
26/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
59/ 100

Competitive context

514 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
Flotufolastat F-18
Washington University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Zenocutuzumab is also rated in:

Solid Tumours Harboring NRG1 FusionDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →